Pages

Thursday, June 19, 2014

ApoCIII Genetic Studies Suggest Oligonucleotide Therapeutics to Generate Next Statin

With ISIS Pharmaceuticals having presented strong phase II data showing that ISIS-ApoCIIIRx leads to ~65% reductions in serum triglycerides, it is now in the lead position to exploit the next statin-like opportunity in cardiovascular disease: ApoCIII inhibition.

Large population studies published yesterday in the New England Journal of Medicine (here and here) have now confirmed that not only very high triglyceride levels are problematic for health (e.g. pancreatitis), but that even normal triglyceride levels may not be optimal.  This is because in those people that harbor a mutation that reduces the activity of the ApoCIII gene by just 50% have roughly half the risk of those with ‘normal genes’ of suffering from a cardiovascular event.  As such, (ApoCIII-related) triglyceride levels have become the second important independent risk factor for cardiovascular disease.

ApoCIII inhibitors like ISIS-ApoCIIIRx are particularly valuable for the industry to develop and commercialize for at least 2 reasons. 

For one, the new studies provide human proof-of-concept that triglyceride lowering via the ApoCIIII route should be beneficial and therefore dramatically lower the risk and cost of outcomes studies.  There may be other ways of lowering triglycerides, but from the experience in lipoproteins, it may not just be a matter of down-regulating triglycerides per se, but also the mechanism of achieving how that goal is achieved.  This could e.g. have critical impact on which forms of triglycerides are affected.

The other reason is that unlike the fish oils (20-30% lowering) and niacins (35-50% lowering with significant side effects) which have achieved only moderate triglyceride reductions, inhibiting the ‘undruggable’ ApoCIII with oligonucleotides has been shown by ISIS to have a much more profound impact on triglyceride levels with additional benefits such as ~40-50% increases in the ‘good’ HDL cholesterol.

As a result, ApoCIII inhibitors could in fact be the real ‘next statin’ for the industry, not the PCSK9 inhibitors which address the same risk factor as statins (LDL cholesterol) and may be largely relegated to the millions that do not tolerate statins.


ISIS Path Forward

Being ahead of the competition by 2 clinical phases for such an exciting target is highly valuable, but also represents challenges to ISIS Pharmaceuticals as the race to competing ApoCIII inhibitors is now officially on.  It is e.g. almost certain that Alnylam will develop an RNAi-based inhibitor, and I would expect the same from Tekmira.

Given the impressive lipid profile of ISIS-ApoCIIIRx and the well-established link between very high triglyceride levels and disease, the subcutaneous ISIS-ApoCIIIRx had been expected to readily obtain marketing approvals for those patient populations (e.g. >500mg/dL) without outcome studies.  Even fish-oil competitor Amarin with much less triglyceride lowering was able to do so.  

However, given the new population genetic evidence and the fact that ISIS-ApoCIIIRx is much more effective in lowering triglycerides, I am wondering whether the threshold for approval without outcomes studies will be somewhat lowered and the initial patient populations therefore widened, including in patients at high-risk of suffering (another) cardiovascular event, but that do not necessarily have very high triglyceride levels.


The next step after that would be outcomes studies in broader populations.  This could be done with ISIS-ApoCIIIRx.  A better idea, however, might be to develop a GalNAc-targeted gen2.5 ASO which would be orally available.  Such a differentiation strategy would also facilitate partnering strategies that the company would pursue and I am almost certain that ISIS-ApoCIIIRx2 will be ISIS' first oral antisense drug.  

And after ApoCIII...how about Apo 'little A' for which ISIS also has clinical studies under way already?

7 comments:

Anonymous said...

Dirk, I'm impressed. As a true scientist you have relied on the “evidence”. Previously ISIS had several failures that were foretold by shaky data. You correctly called those failures, and now preliminary, subtle, but real data shifts to ISIS's favor, and, you correctly, and without prejudice, analyzed the data. YOU'RE THE MAN in RNA!

Anonymous said...

Hello Experiencedmentor. is that you?

Anonymous said...

Benitec data due any day now Dirk. I have some humble pie in my refrigerator for you.

Somebody told me once that this particular pie is best served cold.

Anonymous said...

Callimune safety results are in and second cohort to proceed! The beginning of the ddRNAi validation.

Anonymous said...

Market doesn't react though.

I can hear the excuses for selling out cheaply already.

- Market doesn't understand us

- Cost of development

- Can't be done in Australia

- Need to be closer to like minded people

- It was the government and their damned budget

etc etc etc

Therefore, the BoD unanimously recommend all shareholders accept this bid of 3c.

Anonymous said...

Great safety results from BLT. Nothing we didn't already know and couldn't anticipate.

Begs the question of why none of their other efforts ever got past PI safety.

I guess that then raises other questions of efficacy and toxicity. Something Kay and Dirk will know all about given all the mice they've killed with it.

Makes you wonder what it is PFE saw to warrant ditching out on Tacere in the first place before they once again became BLT.

A clue as the where the future direction of up lies might be found in Stanford going with RGLS on some of their HCV work.

Eg, AU patent 2005240118

Anonymous said...

"why none of their other efforts ever got past PI safety"

Factually, what a load of nonsense.

In fact, so is the rest of your post.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.